About
Stephanie Morris is a Principal at Artesian, which she joined in 2023, where she leads the venture investment process and strategy for the SAVC Fund and Health Transformation vertical. Her background is in deep tech commercialisation, especially in life sciences, and she previously served as Director of Innovation & Translation at MTPConnect and spent five years at Imperial College London in commercialisation and industry partnership roles. She holds an MBA from the University of South Australia, is a Certified Licensing Professional, and has qualifications in business and biomedical science.
Invests in
BiotechDeep TechDigital HealthHealthtechMedical Devices
Experience
- Artesian (Alternative Investments)Principalcurrent2025 โ presentAustralia
- Artesian (Alternative Investments)Investment Manager2023 โ 2025Australia
- BiomeBankNon Executive Directorcurrent2024 โ presentAustralia
- FerronovaNon Executive Directorcurrent2024 โ presentAustralia
- Imperial College LondonConsultant2022 โ 2024London, England, United Kingdom
- Imperial College LondonDirector of Industry Partnerships and Commercialisation, Medicine2019 โ 2022London, United Kingdom
- Imperial College LondonHead of Corporate Partnerships, Medicine2018 โ 2019London, United Kingdom
- TenUConsultant2022 โ 2024Cambridge, England, United Kingdom
- Cure4 Cystic Fibrosis (Cure4CF Foundation Limited)Deputy Chair2022 โ 2023South Australia, Australia
- Cure4 Cystic Fibrosis (Cure4CF Foundation Limited)Director2019 โ 2023London, United Kingdom
- Cure4 Cystic Fibrosis (Cure4CF Foundation Limited)Chair, Research & Commercialisation Sub-Committee2018 โ 2023United Kingdom
- MTPConnectDirector of Innovation & Translation, Adelaide Intermediary Program2022 โ 2023Australia
- Industry Leaders Fund (ILF)ILF Scholars Network, Committee Member2015 โ 2018
- AusBiotechAusBiotech SA Branch, Committee Member2009 โ 2018
- ECH Inc.Manager Corporate Development and Strategic Partnerships2015 โ 2017Adelaide, Australia
- Home Support Services Pty LtdBusiness Innovation Manager2014 โ 2015Adelaide, South Australia
- Madeleine PharmaceuticalsChief Operating Officer2013 โ 2014
- MedvetNational Contracts & Commercial Manager2010 โ 2013
- HospiraScientific Support & Business Development, One 2 Oneยฎ Biologics2007 โ 2010
- University of AdelaideResearch Officer2001 โ 2007
Skills & more
+10 more
Business PlanningTechnology TransferCross-functional Team LeadershipStart-upsNegotiationManagementStrategySpin-outCommercialisationPharmaceutical IndustryFrom Stephanie's professional profile.
Investments
Board seats
BiomeBankFerronova
Per the firm's website.
Colleagues at Artesian
Frequently asked questions
- Who is Stephanie Morris?
- Stephanie Morris is a Principal at Artesian, which she joined in 2023, where she leads the venture investment process and strategy for the SAVC Fund and Health Transformation vertical. Her background is in deep tech commercialisation, especially in life sciences, and she previously served as Director of Innovation & Translation at MTPConnect and spent five years at Imperial College London in commercialisation and industry partnership roles. She holds an MBA from the University of South Australia, is a Certified Licensing Professional, and has qualifications in business and biomedical science.
- Where does Stephanie Morris work?
- Stephanie Morris is Principal at Artesian.
- What does Stephanie Morris invest in?
- Stephanie Morris invests in Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- What boards does Stephanie Morris sit on?
- Stephanie Morris holds tracked board seats at BiomeBank, Ferronova.
- Where did Stephanie Morris go to school?
- Stephanie Morris studied at Certified Licensing Professionals, Inc. (Certified Licensing Professional); Australian Institute of Company Directors (GAICD); University of South Australia (Master of Business Administration (MBA)).
Same school
Also attended Australian Institute of Company Directors137
+ 131 more
Also attended University of South Australia18
+ 12 more
Shared employers
Also worked at Ferronova4
Also worked at Imperial College London132
+ 126 more























%20(2).jpg)














